Phoenix, AZNCT05488548Now EnrollingIRB Ready

Castrate Resistant Prostate Cancer Clinical Trial in Phoenix, AZ

Access cutting-edge castrate resistant prostate cancer treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.

Sponsored by Epigenetix, Inc.

Quick Self-Assessment

See if you qualify for this Phoenix location

Preparing your pre-screening questions…

Expert Care in Phoenix

Access castrate resistant prostate cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related castrate resistant prostate cancer treatment provided free

Apply for This Phoenix Location

Check if you qualify for this castrate resistant prostate cancer clinical trial in Phoenix, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Phoenix

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Phoenix site if eligible
  4. 4Begin participation

About This Castrate Resistant Prostate Cancer Study in Phoenix

A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies

Sponsor: Epigenetix, Inc.

Who Can Participate

Inclusion Criteria

Relapse or refractory castration-resistant prostate cancer (CRPC) following at least one anti-androgen regimen and a docetaxel-containing regimen OR
metastatic or unresectable NUT midline carcinoma for which standard curative or palliative measures do not exist; OR Part 2
relapsed or refractory CMML following at least 4 cycles of hypomethylating agent-containing regimen or hydroxyurea unless demonstration of progression or intolerance;
advanced MF (intermediate or high-risk) following at least one JAK inhibitor-containing regimen or unsuitable candidates for JAK inhibitor treatments. Part 3: advanced MF (intermediate or high-risk) with ≤10% blasts in peripheral blood who have not achieved an adequate response or have lost the response to a JAK inhibitor-containing regimen after being on treatment for at least 3 months. Patients who have other types of relapsed or refractory solid tumors (Part 1) or hematological malignancies (Part 2) with pathological and/or biological features suggesting a potential benefit from dual BET and CBP/p300 inhibition may be enrolled after discussion with and approval from medical monitor and sponsor. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 Life expectancy ≥ 3 months Evaluable disease Adequate bone marrow function:
Hemoglobin ≥ 9.0 g/dL (Part 1)
Absolute neutrophil count (ANC) ≥ 1,500/dL (Part 1)
Platelet count ≥100,000/μL (Part 1) or ≥75,000/μL (Part 3) Adequate renal function: Creatinine clearance (CLcr) ≥ 60 mL/min Adequate liver function: total bilirubin ≤ 1.5 x ULN; alanine aminotransferase (ALT) or aspartate Aminotransferase (AST) ≤ 2.5 x ULN or ≤ 5 x ULN in patients with liver metastases Internal normalized ratio for prothrombin time (INR) ≤ 1.2 in patients not receiving chronic anticoagulation Four weeks from prior anti-cancer therapy including chemotherapy, immunotherapy, investigational anti-cancer therapy or 5 half-lives from targeted agents, radiation and have recovered from prior treatment toxicities to grade 1 or less. Four weeks from major surgery. For fertile men and women, agreement to use effective contraceptive methods duration of study participation and 4 weeks after the last dose of study drug. Ability to understand and willingness to sign the informed consent form.

Exclusion Criteria

New and progressive central nervous system (CNS) metastasis; patients with treated brain metastases are eligible if follow-up brain imaging at least 4 weeks after CNS-directed therapy shows no evidence of progression and the patient is neurologically stable
Corrected QT interval ≥470 msec
Uncontrolled concurrent illnesses including, but not limited to, ongoing active infection requiring intravenous antibiotics or antifungal agents, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would affect compliance with study requirements; patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of EP31670 are eligible for this trial
Pregnant or lactating women
Known history of hepatitis B, hepatitis C requiring antiviral treatment
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Phoenix?

Yes, this clinical trial (NCT05488548) has an active research site in Phoenix, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Castrate Resistant Prostate Cancer Treatment Options in Phoenix, AZ

If you're searching for castrate resistant prostate cancer treatment options in Phoenix, AZ, this clinical trial (NCT05488548) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced castrate resistant prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all castrate resistant prostate cancer clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in Phoenix, AZ

See all prostate cancer clinical trials recruiting in Phoenix — not just this study.

Browse Prostate Cancer Trials in Phoenix →

Browse More Trials by Condition

Prostate Cancer TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Phoenix?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Phoenix, AZ